HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Structure/function reg

This article was originally published in The Tan Sheet

Executive Summary

Future FDA guidance should adopt "innocent construction rule" and allow use of disclaimers, Emord & Associates says in comments filed on behalf of Weider Nutrition, Pure Encapsulations, other supplement firms. "FDA must begin with the unbiased presumption that a structure/function claim that arguably implies disease cure, treatment, prevention or mitigation is intended...to convey a non-disease connotation," comments say. FDA should give firms "option of using a disclaimer that eliminates the disease connotation rather than a 'courtesy letter'" limited to explaining that claim may be used only if approved in a health claim petition or NDA. Several trade groups have said FDA guidance providing examples of supplement claims that would be deemed disease claims is not needed (1"The Tan Sheet" May 28, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel